19 May 2013
Keywords: s-p, vicriviroc, suppresses, hiv, load, through, weeks
Article | 18 February 2008
US drug major Schering-Plough says that final results of a Phase II study showed vicriviroc, its once-daily, next-generation CCR5 HIV ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 February 2008
17 May 2013
© 2013 thepharmaletter.com